RBC Capital has increased its price target on Neurocrine Biosciences (NBIX), citing a revised outlook on the company's stock performance.
Analyst price target changes can influence investor sentiment and stock valuation.
RBC Capital has raised its price target on Neurocrine Biosciences (NBIX). This adjustment reflects a revised outlook on the company's stock performance.
Pick the topics you care about. Get only what matters, on your cadence.
Trading stocks, CFDs, spread betting, futures, and options involves a high level of risk and may not be suitable for all investors. Prices can move rapidly, and losses can occur quickly and exceed your expectations.
